---
title: "BWS Financial maintains Sell rating on Twist Bioscience, $45 price target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299458429.md"
description: "BWS Financial maintains a Sell rating on Twist Bioscience with a $45 price target, implying a 71.1% downside from the September 17 close of $155.56. The analyst cites weak financial performance, insufficient revenue growth, and increasing market competition in the synthetic biology sector as key factors impacting profitability."
datetime: "2026-09-18T13:53:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299458429.md)
  - [en](https://longbridge.com/en/news/299458429.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299458429.md)
generator: "portal-rs"
---

# BWS Financial maintains Sell rating on Twist Bioscience, $45 price target

BWS Financial maintained their Sell rating on Twist Bioscience's stock with a price target of $45.00.

The price target implies a downside of 71.1% from the Sep 17 close of $155.56.

**Key takeaways from the analyst note**

**Weak Financial Performance**: Twist Bioscience has been struggling to generate sufficient revenue growth, leading analysts to question the sustainability of its business model and overall financial health.

**Market Competition and Pricing Pressure**: The synthetic biology space is becoming increasingly competitive, with numerous players entering the market, which could lead to pricing pressure and further impact Twist Bioscience's profitability.

Explore more price target data and ratings for Twist Bioscience on the .

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [TWST.US](https://longbridge.com/en/quote/TWST.US.md)

## Related News & Research

- [Should Biofoundry Market Growth Require Action From Twist Bioscience (TWST) Investors?](https://longbridge.com/en/news/301650928.md)
- [These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?](https://longbridge.com/en/news/301564686.md)
- [Twist Bioscience CEO Emily M. Leproust disposes of USD 910,033 in common shares](https://longbridge.com/en/news/301180941.md)
- [8,175 Twist Bioscience Corporation $TWST Shares Sold by Moody National Bank Trust Division](https://longbridge.com/en/news/301083499.md)
- [These Analysts Revise Their Forecasts On Charles Schwab After Q3 Results](https://longbridge.com/en/news/302122079.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**